Tranexamic Acid; A Glittering Player in the Field of Trauma

Trauma is still the leading cause of mortality and morbidity worldwide with an estimated 5.8 million mortalities every year [1] and approximately 60 million traumatic brain injuries (TBI) annually [2]. Hemorrhage remains the most common preventable cause of mortality and morbidity following trauma either in civilian or military settings [3, 4]. Intracranial bleeding following TBI results in increased intracranial pressure (ICP), brain herniation and cerebral edema which are all secondary insults to the brain parenchyma leading to increase disability and mortality [5]. Thus, the development and administration of antifibrinolytic agents have been the focus of traumatic injuries during the previous decades with the hypothesis of hemorrhage cessation and hemostasis with a medical agent rather than a surgical intervention. These efforts resulted in developing several agents and subsequent large multicenter clinical trials to define the best antifibrinolytic agent for prevention of death following TBI.